PetMeds® Completes Acquisition of PetCareRx

3 years ago

DELRAY BEACH, Fla., April 03, 2023 (GLOBE NEWSWIRE) -- PetMed Express, Inc. (“PetMeds®”) (NASDAQ: PETS), Your Trusted Pet Health Expert™…

Enochian BioSciences’ CEO Letter to Shareholders

3 years ago

Turning the Page; A Promising FutureLOS ANGELES, April 03, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) --  Accelerated Pre-Investigational New Drug…

The International Myeloma Foundation Announces the Annual Miles for Myeloma 5K Run/Walk: 15 Years of Making a Difference in the Myeloma Community

3 years ago

PHILADELPHIA, April 03, 2023 (GLOBE NEWSWIRE) -- The Annual Miles for Myeloma Hybrid 5K Run/Walk will once again “Redefine Being…

Healthcare Triangle Expands Long-Standing Customer Engagement with readabl.ai Medical Document Automation Solution

3 years ago

readabl.ai is a best-in-class AI and language processing model that help customers achieve maximum performance efficiency in workflow automationPLEASANTON, Calif.,…

Comera Life Sciences Announces Expansion of Patent Portfolio Underlying Core Excipient Technology

3 years ago

– Notice of Allowance of U.S. patent application received for expansion of core viscosity reduction claims for excipients in SQore™…

Panbela Announces New Research Agreement with Johns Hopkins University School of Medicine

3 years ago

MINNEAPOLIS, April 03, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics…

Ashvattha Therapeutics to Present Preclinical Data at the AACR and ARVO 2023 Annual Meetings

3 years ago

Preclinical data to be presented at AACR will showcase the potential effect of D-4559, a potent macrophage switching nanomedicine, on…

RespireRx Pharmaceuticals Inc. Discloses Novel Structural Analogs of its GABAA Receptor Potentiator, KRM-II-81 with Antiseizure Efficacy and Antitremor Effects without Sedation.

3 years ago

Glen Rock, N.J., April 03, 2023 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTC Markets: RSPI) (“RespireRx” or the “Company”), a…

CPI-818 Data Highlights Potential for ITK Inhibition as a New Immunotherapy Approach for the Treatment of T Cell Lymphoma

3 years ago

Interim data from Phase 1/1b clinical trial of CPI-818, including new evidence supporting the recently implemented minimum absolute lymphocyte count…

ContraFect Announces Initiation of a Phase 1b/2 Study of Exebacase in Patients with Chronic Prosthetic Joint Infections of the Knee

3 years ago

YONKERS, New York, April 03, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the…